Neurostimulation Devices Market, 2012-2017
Introduction
Neurostimulation devices are gaining acceptance as therapy alternative for certain chronic conditions such as pain. These devices have also found use in management of movement disorders including Parkinson’s disease and epilepsy. The currently available neurostimulators mainly focus on spinal cord stimulation (SCS), deep brain stimulation (DBS), vagus nerve stimulation (VNS) and sacral nerve stimulation (SNS).
The market is still niche, with limited number of devices available in the market. The 2012-2017 period will see the launch of several new devices, targeting new nerves of the nervous system and intending to manage new indications. Currently most of the available neurostimulation devices require surgical implantation as well as replacement surgeries after every few years. A number of companies are now focusing on the development of non-invasive transcutaneous or transdermal neurostimulation devices, which will drive the progressive growth in the market.
However, there are challenges to market entry for smaller companies, particularly due to market domination by few large medical device developers. This market model, however, did not deter the US based company Cyberonics from making its own niche in the VNS market, where it currently is the market leader. Smaller medical device companies with innovative technology have huge potential for growth in this yet unexplored market. Amongst other things, this report provides a detailed overview of the most promising pipeline technology and devices.
Scope of the Report
The Neurostimulation Devices Market report extensively examines various segments of the neurostimulation devices. In this report, we have identified the features of various devices, their benefits over conventional drug therapy while understanding the epidemiology of associated neurological diseases. The report focuses on analysing the existing market size and potential future growth of these devices across different segments and regions. We have also discussed the performance of leading players in the industry and the likely future developments driven by these companies.
The report highlights both the regional and global trends of the neurostimulation devices in the following key segments:
The market forecasts across different segments, regions, companies have been presented till 2017. 2011 is the base year and actual figures have been taken, analysed from publicly available information. Unless otherwise specified, all figures are presented in USD.
While the leading commercial devices, companies and segments have been considered thoroughly, the report also provides details on the pipeline devices in various stages of clinical trials. In addition, it highlights information on the regulatory approvals (e.g. FDA and CE mark) for these devices in the US, Europe and other markets.
Key Highlights
1. The global neurostimulation devices market is likely to achieve sales of USD 6,533 MM by 2017, growing at a compounded annual growth rate (CAGR) of 17.9% from 2011 to 2017.
2. Spinal Cord Stimulation (SCS) accounted for 50.5% of the sales of the currently marketed neurostimulation devices in 2011. This segment will continue to be the largest segment in the neurostimulation devices market over the forecast period (2012 to 2017).
3. Deep Brain Stimulation (DBS) segment will be the fastest growing segment during the forecast period (2012-2017), primarily driven by expansion of indications targeted by this class of devices and unavailability of effective drugs for many of the targeted indications.
4. The overall market is dominated by four leading companies - Medtronic, St. Jude Medical, Boston Scientific and Cyberonics. Together these companies accounted for about 90% of the total market in 2011.
5. The US was the largest market for neurostimulation devices in 2011 and accounted for 81.9% of the total market in 2011.
6. The US was also the largest market for DBS devices, accounting more than 70% of the sales in 2011.
7. The high cost of therapy is a deterrent to market acceptance and gaining reimbursement for the devices will be an important milestone for the device developers.
8. A number of companies are developing non-invasive neurostimulation devices, which will help increase the adoption of these devices as treatment alternative.
Research Methodology
Most of the data presented in this report has been gathered by secondary research. We have also conducted interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on the emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will shape up across different regions and drug segments. Where possible, the available data has been checked for accuracy from multiple sources of information.
The secondary sources of information include
The 2011 data are actual sales as reported in the company annual reports and represent full year sales from January to December 2011. However, for some companies for which the financial year ends in April, sales for 2011 have been estimated using specific quarterly data. In these cases, the 2011 sales have been approximated as sales for the period February 2011 - January 2012.
Chapter Outlines
Chapter 1 is a high level Executive Summary of the key market insights presented in the report.
Chapter 2 provides a general overview about neurostimulation and its therapeutic applications. This chapter also highlights different segments of neurostimulation and focuses on associated risk factors and benefits.
Chapter 3 highlights the global market for neurostimulation devices in 2011 and the likely future growth trends till 2017. This chapter analyses the market with respect to leading device segments and leading companies.
Chapter 4 focuses specifically on the market for Spinal Cord Stimulation (SCS) devices in 2011 and the growth expectations till 2017. This chapter provides details on the market size by leading regions and companies. It also contains a SWOT analysis and detailed profile of leading devices within this segment. We have looked at both the existing commercial devices and devices in the pipeline.
Chapter 5 focuses specifically on the market for Deep Brain Stimulation (DBS) devices in 2011 and the growth expectations till 2017. This chapter provides details on the market size by leading regions and companies. It also contains a SWOT analysis and detailed profile of leading devices within this segment. We have looked at both the existing commercial devices and devices in the pipeline.
Chapter 6 focuses specifically on the market for Vagal Nerve Stimulation (VNS) devices in 2011 and the growth expectations till 2017. This chapter provides details on the market size by leading regions and companies. It also contains a SWOT analysis and detailed profile of leading devices within this segment. We have looked at both the existing commercial devices and devices in the pipeline.
Chapter 7 focuses on the market for remaining neurostimulation devices in 2011 and the growth expectations till 2017. This chapter provides details on the market size for Sacral Nerve Stimulation (SNS) and other technologies. As with the other segments, we have looked at both the existing commercial devices and devices in the pipeline.
Chapter 8 analyses the regional markets (the US, Europe, Japan and RoW) for neurostimulation devices. Within each region, the chapter focuses on the existing market size and likely future growth. We have also identified various technological, commercial and regulatory trends for each specific region.
Chapter 9 provides profiles of the key companies in neurostimulation devices market. Each company profile includes information such as market size, financial performance, geographical presence, marketed / pipeline devices, role and strategy for manufactured devices and recent developments.
Chapter 10 summarises the overall report. In this chapter, we provide a recap of the key takeaways and our independent opinion based on the research and analysis described in previous chapters.
Neurostimulation devices are gaining acceptance as therapy alternative for certain chronic conditions such as pain. These devices have also found use in management of movement disorders including Parkinson’s disease and epilepsy. The currently available neurostimulators mainly focus on spinal cord stimulation (SCS), deep brain stimulation (DBS), vagus nerve stimulation (VNS) and sacral nerve stimulation (SNS).
The market is still niche, with limited number of devices available in the market. The 2012-2017 period will see the launch of several new devices, targeting new nerves of the nervous system and intending to manage new indications. Currently most of the available neurostimulation devices require surgical implantation as well as replacement surgeries after every few years. A number of companies are now focusing on the development of non-invasive transcutaneous or transdermal neurostimulation devices, which will drive the progressive growth in the market.
However, there are challenges to market entry for smaller companies, particularly due to market domination by few large medical device developers. This market model, however, did not deter the US based company Cyberonics from making its own niche in the VNS market, where it currently is the market leader. Smaller medical device companies with innovative technology have huge potential for growth in this yet unexplored market. Amongst other things, this report provides a detailed overview of the most promising pipeline technology and devices.
Scope of the Report
The Neurostimulation Devices Market report extensively examines various segments of the neurostimulation devices. In this report, we have identified the features of various devices, their benefits over conventional drug therapy while understanding the epidemiology of associated neurological diseases. The report focuses on analysing the existing market size and potential future growth of these devices across different segments and regions. We have also discussed the performance of leading players in the industry and the likely future developments driven by these companies.
The report highlights both the regional and global trends of the neurostimulation devices in the following key segments:
- Spinal Cord Stimulation (SCS)
- Deep Brain Stimulation (DBS)
- Vagus Nerve Stimulation (VNS)
- Sacral Nerve Stimulation (SNS)
The market forecasts across different segments, regions, companies have been presented till 2017. 2011 is the base year and actual figures have been taken, analysed from publicly available information. Unless otherwise specified, all figures are presented in USD.
While the leading commercial devices, companies and segments have been considered thoroughly, the report also provides details on the pipeline devices in various stages of clinical trials. In addition, it highlights information on the regulatory approvals (e.g. FDA and CE mark) for these devices in the US, Europe and other markets.
Key Highlights
1. The global neurostimulation devices market is likely to achieve sales of USD 6,533 MM by 2017, growing at a compounded annual growth rate (CAGR) of 17.9% from 2011 to 2017.
2. Spinal Cord Stimulation (SCS) accounted for 50.5% of the sales of the currently marketed neurostimulation devices in 2011. This segment will continue to be the largest segment in the neurostimulation devices market over the forecast period (2012 to 2017).
3. Deep Brain Stimulation (DBS) segment will be the fastest growing segment during the forecast period (2012-2017), primarily driven by expansion of indications targeted by this class of devices and unavailability of effective drugs for many of the targeted indications.
4. The overall market is dominated by four leading companies - Medtronic, St. Jude Medical, Boston Scientific and Cyberonics. Together these companies accounted for about 90% of the total market in 2011.
5. The US was the largest market for neurostimulation devices in 2011 and accounted for 81.9% of the total market in 2011.
6. The US was also the largest market for DBS devices, accounting more than 70% of the sales in 2011.
7. The high cost of therapy is a deterrent to market acceptance and gaining reimbursement for the devices will be an important milestone for the device developers.
8. A number of companies are developing non-invasive neurostimulation devices, which will help increase the adoption of these devices as treatment alternative.
Research Methodology
Most of the data presented in this report has been gathered by secondary research. We have also conducted interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on the emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will shape up across different regions and drug segments. Where possible, the available data has been checked for accuracy from multiple sources of information.
The secondary sources of information include
- Annual reports
- Investor presentations
- SEC filings
- Industry databases
- News releases from company websites
- Government policy documents
- Other analysts’ opinion reports
The 2011 data are actual sales as reported in the company annual reports and represent full year sales from January to December 2011. However, for some companies for which the financial year ends in April, sales for 2011 have been estimated using specific quarterly data. In these cases, the 2011 sales have been approximated as sales for the period February 2011 - January 2012.
Chapter Outlines
Chapter 1 is a high level Executive Summary of the key market insights presented in the report.
Chapter 2 provides a general overview about neurostimulation and its therapeutic applications. This chapter also highlights different segments of neurostimulation and focuses on associated risk factors and benefits.
Chapter 3 highlights the global market for neurostimulation devices in 2011 and the likely future growth trends till 2017. This chapter analyses the market with respect to leading device segments and leading companies.
Chapter 4 focuses specifically on the market for Spinal Cord Stimulation (SCS) devices in 2011 and the growth expectations till 2017. This chapter provides details on the market size by leading regions and companies. It also contains a SWOT analysis and detailed profile of leading devices within this segment. We have looked at both the existing commercial devices and devices in the pipeline.
Chapter 5 focuses specifically on the market for Deep Brain Stimulation (DBS) devices in 2011 and the growth expectations till 2017. This chapter provides details on the market size by leading regions and companies. It also contains a SWOT analysis and detailed profile of leading devices within this segment. We have looked at both the existing commercial devices and devices in the pipeline.
Chapter 6 focuses specifically on the market for Vagal Nerve Stimulation (VNS) devices in 2011 and the growth expectations till 2017. This chapter provides details on the market size by leading regions and companies. It also contains a SWOT analysis and detailed profile of leading devices within this segment. We have looked at both the existing commercial devices and devices in the pipeline.
Chapter 7 focuses on the market for remaining neurostimulation devices in 2011 and the growth expectations till 2017. This chapter provides details on the market size for Sacral Nerve Stimulation (SNS) and other technologies. As with the other segments, we have looked at both the existing commercial devices and devices in the pipeline.
Chapter 8 analyses the regional markets (the US, Europe, Japan and RoW) for neurostimulation devices. Within each region, the chapter focuses on the existing market size and likely future growth. We have also identified various technological, commercial and regulatory trends for each specific region.
Chapter 9 provides profiles of the key companies in neurostimulation devices market. Each company profile includes information such as market size, financial performance, geographical presence, marketed / pipeline devices, role and strategy for manufactured devices and recent developments.
Chapter 10 summarises the overall report. In this chapter, we provide a recap of the key takeaways and our independent opinion based on the research and analysis described in previous chapters.
1 EXECUTIVE SUMMARY
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
1.4. Key Highlights
1.4.1. Spinal Cord Stimulation has the Major Share in Neurostimulation Devices Market
1.4.2. Medtronic was the Unbeaten Market Leader in 2011
1.4.3. The US was the Largest Market for Neurostimulation Devices in 2011
1.4.4. Bulk of the Growth Will be Driven by Launch of Pipeline Devices
1.4.5. A Rapidly Growing Market With Attractive Opportunities
2 INTRODUCTION TO NEUROSTIMULATION
2.1. Basics of Neuromodulation and Neurostimulation
2.2. Types of Neurostimulation Therapies
2.2.1. Spinal Cord Stimulation (SCS)
2.2.2. Deep Brain Stimulation (DBS)
2.2.3. Vagus Nerve Stimulation (VNS)
2.2.4. Sacral Nerve Stimulation (SNS)
2.2.5. Peripheral Nerve Stimulation (PNS)
2.3. Applications of Neurostimulation
3 NEUROSTIMULATION DEVICES MARKET, 2011-2017
3.1. Overview
3.2. State of Neurostimulation Devices Market in 2011
3.2.1. Spinal Cord Stimulator (SCS) Devices Dominated the Market in 2011
3.2.2. Medtronic was the Leading Company in the Market, Outpacing the Rest by a Huge Margin
3.2.2.1. The Market is Dominated by a Few Large Companies
3.2.3. Device Sales in the Neurostimulation Market
3.3. Neurostimulation Devices Market Forecast, 2011-2017
3.3.1. SCS Devices Segment will Lose its Market Share to Other Segments
4 SPINAL CORD STIMULATION (SCS) DEVICES MARKET, 2011-2017
4.1. Overview
4.2. SCS Devices Market in 2011
4.2.1. The US was the Largest Market for SCS Devices
4.2.2. Medtronic Dominated the SCS Devices Market with its Wide Range of Devices
4.3. SCS Devices in the Market
4.3.1. Precision Plus (Boston Scientific)
4.3.1.1. Approval Date / Launch Date
4.3.2. Eon Mini (St. Jude Medical)
4.3.3. RestoreUltra (Medtronic)
4.4. SCS Devices in Development
4.5. SCS Devices Market, 2012-2017
4.5.1. Factors Driving Growth of SCS Devices Market
4.5.2. US Will Continue to be the Largest Market for SCS Devices
4.6. SCS Devices: SWOT Analysis
4.6.1. Strengths
4.6.1.1. Minimally Invasive Procedure that Improves Quality of Life and Reduces the Use of Medications
4.6.1.2. Technological Advancements
4.6.1.3. A Cost Effective Treatment Option
4.6.2. Weaknesses
4.6.2.1. High Price of SCS Device and Initial Treatment Cost
4.6.2.2. Unknown Mechanism of SCS Therapy
4.6.2.3. Potential Complications and Side effects of SCS Therapy
4.6.2.4. Only Provides Symptomatic Relief
4.6.3. Opportunities
4.6.3.1. Expansion of Indication for SCS
4.6.3.2. Need for MRI Safe Devices
4.6.3.3. Increasing Prevalence of Chronic Pain
4.6.4. Threats
4.6.4.1. Reimbursement
4.6.4.2. Device Recalls
5 DEEP BRAIN STIMULATION (DBS) DEVICES MARKET, 2011-2017
5.1. Overview
5.2. DBS Devices Market in 2011
5.2.1. The US was the Largest Market for DBS Devices
5.2.2. Medtronic Dominated the DBS Market in 2011
5.2.2.1. Reason’s for Medtronic’s Dominance
5.2.2.2. Medtronic Likely to Lose its Monopoly in the DBS Market
5.3. DBS Devices in the Market
5.3.1. Activa Series, Medtronic
5.3.2. Libra/Libra XP, St. Jude Medical
5.4. DBS Devices in Development
5.4.1. Libra/Libra XP, St. Jude Medical
5.4.2. Vercise DBS, Boston Scientific
5.5. DBS Devices Market, 2012-2017
5.5.1. Growth Driving Factors
5.5.2. US Will Continue to be the Largest Market for DBS Devices
5.6. DBS Devices: SWOT Analysis
5.6.1. Strengths
5.6.1.1. Last Resort Option for Patients with Parkinson’s Disease
5.6.1.2. High Burden of Parkinson’s Disease
5.6.1.3. DBS is a Reversible Surgical Treatment
5.6.2. Weaknesses
5.6.2.1. High Cost of Treatment
5.6.2.2. Potential Complications And Side Effects of DBS Therapy
5.6.2.3. Only Provides Symptomatic Relief
5.6.3. Opportunities
5.6.3.1. Ageing Global Population
5.6.3.2. Technological Developments: An Attractive Opportunity
5.6.3.3. Expansion of Indication for DBS
5.6.3.4. Need for MRI Safe Devices
5.6.4. Threats
5.6.4.1. Reimbursement
5.6.4.2. Device Recalls (Brio)
5.6.4.3. Upcoming Disease Modifying Drugs
6 VAGUS NERVE STIMULATION (VNS) DEVICES MARKET, 2011-2017
6.1. Overview
6.2. VNS Devices Market in 2011
6.2.1. Cyberonics Dominated the VNS Market in 2011
6.2.2. New Companies will Drive Competition and Challenge Cyberonics
6.2.3. US was the Largest Market for VNS Devices
6.2.4. Sale of VNS Devices for Refractory Epilepsy Generated Majority of Revenues in 2011
6.3. VNS Devices in the Market
6.3.1. VNS Devices, Cyberonics
6.3.1.1. AspireHC Generator
6.3.2. Maestro Rechargeable (RC) System, EnteroMedics
6.3.3. CardioFit, BioControl Medical
6.3.4. FitNeS, CerebralRx
6.4. VNS Devices in Development
6.4.1. NEMOS, Cerbomed
6.4.2. ADNS-300, Neurotech
6.4.3. AspireSR, Cyberonics
6.5. VNS Devices Market, 2012-2017
6.5.1. Factors Driving Growth of VNS Devices Market
6.5.2. US Will Continue to be the Largest Market for VNS Devices
6.6. VNS Devices: SWOT Analysis
6.6.1. Strengths
6.6.1.1. High Burden of Epilepsy
6.6.1.2. Huge Number of Patients are Resistant to Antiepileptic Drugs (AED)
6.6.1.3. Easy Surgical Procedure
6.6.2. Weaknesses
6.6.2.1. High Price of VNS Therapy
6.6.2.2. Side Effects of VNS therapy
6.6.2.3. Unknown Mechanism of Action
6.6.3. Opportunities
6.6.3.1. Expansion of Imaging Options
6.6.3.2. Companies Exploring New Indications for VNS Therapy
6.6.4. Threats
6.6.4.1. Reimbursement
6.6.4.2. Competition from Other Neurostimulation Technologies
7 OTHER NEUROSTIMULATION DEVICES MARKET, 2011-2017
7.1. Sacral Nerve Stimulation (SNS) Devices Market, 2011-2017
7.1.1. Medtronic’s InterStim was the Only Marketed SNS Device in 2011
7.1.2. SNS Devices Market, 2012-2017
7.2. Other Neurostimulation Devices in the Market, 2012
7.2.1. Urgent PC, Uroplasty
7.2.2. abiliti, IntraPace
7.2.3. aura6000, ImThera Medical
7.2.4. Barostim neo, CVRx
7.3. Other Neurostimulation Devices in Development
7.3.1. Europe is the Preferred Destination for Device Developers
7.3.2. Companies are Targeting New Indications
7.3.3. Large Medical Device Manufacturers are Providing Financial Backing
7.3.4. Companies are Exploring Non-Invasive Technologies
8 REGIONAL MARKETS FOR NEUROSTIMULATION DEVICES 2011
8.1. Overview
8.2. The US Market for Neurostimulation Devices, 2011-2017
8.2.1. Regulatory Approval of Medical Devices in the US
8.2.2. Leading Segments in the US Neurostimulation Devices Market, 2011
8.2.2.1. Reasons for Dominance of the US Market
8.2.3. Competition in the US Market: Companies and Devices
8.2.4. The US Neurostimulation Devices Market Forecast, 2012-2017
8.3. European Market for Neurostimulation Devices, 2011-2017
8.3.1. Medical Device Spending in Europe
8.3.2. Regulation of Active Implantable Devices in Europe
8.3.3. Leading Segments in the European Neurostimulation Devices Market, 2011
8.3.4. Leading Countries in the European Neurostimulation Devices Market, 2011
8.3.5. Competition in the European Market: Companies and Products
8.3.6. European Neurostimulation Devices Market, 2012-2017
8.3.6.1. Patient Demographics Supporting Growth of Neurostimulation Devices in Europe
8.4. Rest of the World Markets for Neurostimulation Devices, 2011-2017
8.4.1. The Japanese Market for Neurostimulation Devices
8.4.1.1. Regulation of Medical Devices in Japan
8.4.1.2. Devices Available in the Japanese Market, 2011
8.4.2. The Chinese Market for Neurostimulation Devices, 2011
9 PROFILES OF LEADING COMPANIES
9.1. Medtronic
9.1.1. Geographical Presence
9.1.2. Financial Performance
9.1.3. Marketed And Pipeline Devices
9.1.4. Recent Developments
9.2. St. Jude Medical
9.2.1. Geographical Presence
9.2.2. Financial Performance
9.2.3. Marketed And Pipeline Devices
9.3. Boston Scientific
9.3.1. Geographical Presence
9.3.2. Financial Performance
9.3.3. Marketed And Pipeline Devices
9.3.4. Recent Developments
9.4. Cyberonics
9.4.1. Geographical Presence
9.4.2. Financial Performance
9.4.3. Marketed And Pipeline Devices
9.4.4. Recent Developments
10 CONCLUSIONS
10.1. Neurological Diseases: Increasing Burden on the Healthcare Systems
10.2. Current and Future State of The Neurostimulation Devices Market
10.3. Attractiveness Of The Pipeline
10.4. Key Driving Factors
10.5. Concluding Remarks
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
1.4. Key Highlights
1.4.1. Spinal Cord Stimulation has the Major Share in Neurostimulation Devices Market
1.4.2. Medtronic was the Unbeaten Market Leader in 2011
1.4.3. The US was the Largest Market for Neurostimulation Devices in 2011
1.4.4. Bulk of the Growth Will be Driven by Launch of Pipeline Devices
1.4.5. A Rapidly Growing Market With Attractive Opportunities
2 INTRODUCTION TO NEUROSTIMULATION
2.1. Basics of Neuromodulation and Neurostimulation
2.2. Types of Neurostimulation Therapies
2.2.1. Spinal Cord Stimulation (SCS)
2.2.2. Deep Brain Stimulation (DBS)
2.2.3. Vagus Nerve Stimulation (VNS)
2.2.4. Sacral Nerve Stimulation (SNS)
2.2.5. Peripheral Nerve Stimulation (PNS)
2.3. Applications of Neurostimulation
3 NEUROSTIMULATION DEVICES MARKET, 2011-2017
3.1. Overview
3.2. State of Neurostimulation Devices Market in 2011
3.2.1. Spinal Cord Stimulator (SCS) Devices Dominated the Market in 2011
3.2.2. Medtronic was the Leading Company in the Market, Outpacing the Rest by a Huge Margin
3.2.2.1. The Market is Dominated by a Few Large Companies
3.2.3. Device Sales in the Neurostimulation Market
3.3. Neurostimulation Devices Market Forecast, 2011-2017
3.3.1. SCS Devices Segment will Lose its Market Share to Other Segments
4 SPINAL CORD STIMULATION (SCS) DEVICES MARKET, 2011-2017
4.1. Overview
4.2. SCS Devices Market in 2011
4.2.1. The US was the Largest Market for SCS Devices
4.2.2. Medtronic Dominated the SCS Devices Market with its Wide Range of Devices
4.3. SCS Devices in the Market
4.3.1. Precision Plus (Boston Scientific)
4.3.1.1. Approval Date / Launch Date
4.3.2. Eon Mini (St. Jude Medical)
4.3.3. RestoreUltra (Medtronic)
4.4. SCS Devices in Development
4.5. SCS Devices Market, 2012-2017
4.5.1. Factors Driving Growth of SCS Devices Market
4.5.2. US Will Continue to be the Largest Market for SCS Devices
4.6. SCS Devices: SWOT Analysis
4.6.1. Strengths
4.6.1.1. Minimally Invasive Procedure that Improves Quality of Life and Reduces the Use of Medications
4.6.1.2. Technological Advancements
4.6.1.3. A Cost Effective Treatment Option
4.6.2. Weaknesses
4.6.2.1. High Price of SCS Device and Initial Treatment Cost
4.6.2.2. Unknown Mechanism of SCS Therapy
4.6.2.3. Potential Complications and Side effects of SCS Therapy
4.6.2.4. Only Provides Symptomatic Relief
4.6.3. Opportunities
4.6.3.1. Expansion of Indication for SCS
4.6.3.2. Need for MRI Safe Devices
4.6.3.3. Increasing Prevalence of Chronic Pain
4.6.4. Threats
4.6.4.1. Reimbursement
4.6.4.2. Device Recalls
5 DEEP BRAIN STIMULATION (DBS) DEVICES MARKET, 2011-2017
5.1. Overview
5.2. DBS Devices Market in 2011
5.2.1. The US was the Largest Market for DBS Devices
5.2.2. Medtronic Dominated the DBS Market in 2011
5.2.2.1. Reason’s for Medtronic’s Dominance
5.2.2.2. Medtronic Likely to Lose its Monopoly in the DBS Market
5.3. DBS Devices in the Market
5.3.1. Activa Series, Medtronic
5.3.2. Libra/Libra XP, St. Jude Medical
5.4. DBS Devices in Development
5.4.1. Libra/Libra XP, St. Jude Medical
5.4.2. Vercise DBS, Boston Scientific
5.5. DBS Devices Market, 2012-2017
5.5.1. Growth Driving Factors
5.5.2. US Will Continue to be the Largest Market for DBS Devices
5.6. DBS Devices: SWOT Analysis
5.6.1. Strengths
5.6.1.1. Last Resort Option for Patients with Parkinson’s Disease
5.6.1.2. High Burden of Parkinson’s Disease
5.6.1.3. DBS is a Reversible Surgical Treatment
5.6.2. Weaknesses
5.6.2.1. High Cost of Treatment
5.6.2.2. Potential Complications And Side Effects of DBS Therapy
5.6.2.3. Only Provides Symptomatic Relief
5.6.3. Opportunities
5.6.3.1. Ageing Global Population
5.6.3.2. Technological Developments: An Attractive Opportunity
5.6.3.3. Expansion of Indication for DBS
5.6.3.4. Need for MRI Safe Devices
5.6.4. Threats
5.6.4.1. Reimbursement
5.6.4.2. Device Recalls (Brio)
5.6.4.3. Upcoming Disease Modifying Drugs
6 VAGUS NERVE STIMULATION (VNS) DEVICES MARKET, 2011-2017
6.1. Overview
6.2. VNS Devices Market in 2011
6.2.1. Cyberonics Dominated the VNS Market in 2011
6.2.2. New Companies will Drive Competition and Challenge Cyberonics
6.2.3. US was the Largest Market for VNS Devices
6.2.4. Sale of VNS Devices for Refractory Epilepsy Generated Majority of Revenues in 2011
6.3. VNS Devices in the Market
6.3.1. VNS Devices, Cyberonics
6.3.1.1. AspireHC Generator
6.3.2. Maestro Rechargeable (RC) System, EnteroMedics
6.3.3. CardioFit, BioControl Medical
6.3.4. FitNeS, CerebralRx
6.4. VNS Devices in Development
6.4.1. NEMOS, Cerbomed
6.4.2. ADNS-300, Neurotech
6.4.3. AspireSR, Cyberonics
6.5. VNS Devices Market, 2012-2017
6.5.1. Factors Driving Growth of VNS Devices Market
6.5.2. US Will Continue to be the Largest Market for VNS Devices
6.6. VNS Devices: SWOT Analysis
6.6.1. Strengths
6.6.1.1. High Burden of Epilepsy
6.6.1.2. Huge Number of Patients are Resistant to Antiepileptic Drugs (AED)
6.6.1.3. Easy Surgical Procedure
6.6.2. Weaknesses
6.6.2.1. High Price of VNS Therapy
6.6.2.2. Side Effects of VNS therapy
6.6.2.3. Unknown Mechanism of Action
6.6.3. Opportunities
6.6.3.1. Expansion of Imaging Options
6.6.3.2. Companies Exploring New Indications for VNS Therapy
6.6.4. Threats
6.6.4.1. Reimbursement
6.6.4.2. Competition from Other Neurostimulation Technologies
7 OTHER NEUROSTIMULATION DEVICES MARKET, 2011-2017
7.1. Sacral Nerve Stimulation (SNS) Devices Market, 2011-2017
7.1.1. Medtronic’s InterStim was the Only Marketed SNS Device in 2011
7.1.2. SNS Devices Market, 2012-2017
7.2. Other Neurostimulation Devices in the Market, 2012
7.2.1. Urgent PC, Uroplasty
7.2.2. abiliti, IntraPace
7.2.3. aura6000, ImThera Medical
7.2.4. Barostim neo, CVRx
7.3. Other Neurostimulation Devices in Development
7.3.1. Europe is the Preferred Destination for Device Developers
7.3.2. Companies are Targeting New Indications
7.3.3. Large Medical Device Manufacturers are Providing Financial Backing
7.3.4. Companies are Exploring Non-Invasive Technologies
8 REGIONAL MARKETS FOR NEUROSTIMULATION DEVICES 2011
8.1. Overview
8.2. The US Market for Neurostimulation Devices, 2011-2017
8.2.1. Regulatory Approval of Medical Devices in the US
8.2.2. Leading Segments in the US Neurostimulation Devices Market, 2011
8.2.2.1. Reasons for Dominance of the US Market
8.2.3. Competition in the US Market: Companies and Devices
8.2.4. The US Neurostimulation Devices Market Forecast, 2012-2017
8.3. European Market for Neurostimulation Devices, 2011-2017
8.3.1. Medical Device Spending in Europe
8.3.2. Regulation of Active Implantable Devices in Europe
8.3.3. Leading Segments in the European Neurostimulation Devices Market, 2011
8.3.4. Leading Countries in the European Neurostimulation Devices Market, 2011
8.3.5. Competition in the European Market: Companies and Products
8.3.6. European Neurostimulation Devices Market, 2012-2017
8.3.6.1. Patient Demographics Supporting Growth of Neurostimulation Devices in Europe
8.4. Rest of the World Markets for Neurostimulation Devices, 2011-2017
8.4.1. The Japanese Market for Neurostimulation Devices
8.4.1.1. Regulation of Medical Devices in Japan
8.4.1.2. Devices Available in the Japanese Market, 2011
8.4.2. The Chinese Market for Neurostimulation Devices, 2011
9 PROFILES OF LEADING COMPANIES
9.1. Medtronic
9.1.1. Geographical Presence
9.1.2. Financial Performance
9.1.3. Marketed And Pipeline Devices
9.1.4. Recent Developments
9.2. St. Jude Medical
9.2.1. Geographical Presence
9.2.2. Financial Performance
9.2.3. Marketed And Pipeline Devices
9.3. Boston Scientific
9.3.1. Geographical Presence
9.3.2. Financial Performance
9.3.3. Marketed And Pipeline Devices
9.3.4. Recent Developments
9.4. Cyberonics
9.4.1. Geographical Presence
9.4.2. Financial Performance
9.4.3. Marketed And Pipeline Devices
9.4.4. Recent Developments
10 CONCLUSIONS
10.1. Neurological Diseases: Increasing Burden on the Healthcare Systems
10.2. Current and Future State of The Neurostimulation Devices Market
10.3. Attractiveness Of The Pipeline
10.4. Key Driving Factors
10.5. Concluding Remarks
LIST OF TABLES
TABLE 4.1 List of Some Approved SCS Devices, 2012
TABLE 4.2 List of SCS Devices Under Development, 2012
TABLE 5.1 List of Approved DBS Devices, 2012
TABLE 5.2 List of DBS Devices Under Development, 2012
TABLE 5.3 Global Population, 65 and Above - 2010, 2015 and 2020
TABLE 6.1 List of Approved VNS Devices, 2012
TABLE 6.2 List of VNS Devices Under Development, 2012
TABLE 7.1 List of Some Other Approved Neurostimulation Devices in the Market, 2012
TABLE 7.2 List of Some Neurostimulation Devices in Pipeline, 2012
TABLE 8.1 Classification of Medical Devices in the US
TABLE 8.2 Population Over 65 in the US and Selected Countries in Europe, 2010, 2015 and 2020 (%)
TABLE 11.1 Neurostimulation Devices Market, 2011 - By Leading Segments (USD MM, %)
TABLE 11.2 Neurostimulation Devices Market, 2011 - By Leading Companies (USD MM, %)
TABLE 11.3 Sales of Some Neurostimulation Devices, 2011 (USD MM)
TABLE 11.4 Neurostimulation Devices Market Forecast - By Leading Segments, 2012-2017 (USD MM)
TABLE 11.5 Market Shares of Leading Segments in the Neurostimulation Devices Market, 2011-2017 (%)
TABLE 11.6 SCS Devices Market, 2011 - By Leading Regions (USD MM, %)
TABLE 11.7 SCS Devices Market, 2011 - By Leading Companies (USD MM, %)
TABLE 11.8 SCS Devices Market Forecast - By Leading Regions, 2012-2017 (USD MM)
TABLE 11.9 Market Shares of Leading Segments in the SCS Devices Market, 2011-2017 (%)
TABLE 11.10 DBS Devices Market, 2011 - By Leading Regions (USD MM, %)
TABLE 11.11 DBS Devices Market, 2011 - By Leading Companies (USD MM, %)
TABLE 11.12 DBS Devices Market Forecast - By Leading Regions, 2012-2017 (USD MM)
TABLE 11.13 Market Shares of Leading Segments in the DBS Devices Market, 2011-2017 (%)
TABLE 11.14 VNS Devices Market, 2011 - By Leading Regions (USD MM, %)
TABLE 11.15 VNS Devices Market, 2011 - By Indications (USD MM, %)
TABLE 11.16 VNS Devices Market Forecast - By Leading Regions, 2012-2017 (USD MM)
TABLE 11.17 Market Shares of Leading Segments in the VNS Devices Market, 2011-2017 (%)
TABLE 11.18 Neurostimulation Devices Market, 2011 - By Leading Regions (USD MM, %)
TABLE 11.19 The US Neurostimulation Devices Market, 2011 - By Leading Segments (USD MM, %)
TABLE 11.20 The US Neurostimulation Devices Market, 2011 - By Leading Companies (USD MM, %)
TABLE 11.21 The US Neurostimulation Devices Market Forecast - By Leading Segments, 2012-2017 (USD MM)
TABLE 11.22 European Neurostimulation Devices Market, 2011 - By Leading Segments (USD MM, %)
TABLE 11.23 European Neurostimulation Devices Market, 2011 - By Leading Countries (USD MM, %)
TABLE 11.24 European Neurostimulation Devices Market Forecast - By Leading Segments, 2012-2017 (USD MM)
TABLE 11.25 Rest of the World Neurostimulation Devices Market Forecast - By Leading Segments, 2012-2017 (USD MM)
TABLE 11.26 Market Shares of Leading Regions in the Neurostimulation Devices Market, 2011-2017 (%)
TABLE 11.27 Medtronic - Sales by Business Segments (USD MM, %)
TABLE 11.28 Medtronic Neuromodulation Segment - Sales by Region (USD MM, %)
TABLE 11.29 St. Jude Medical - Sales by Business Segments (USD MM, %)
TABLE 11.30 St. Jude Medical Neuromodulation Segment - Sales by Region (USD MM, %)
TABLE 11.31 Boston Scientific - Sales by Business Segments (USD MM, %)
TABLE 11.32 Boston Scientific Neuromodulation Segment - Sales by Region (USD MM, %)
TABLE 11.33 Cyberonics - Sales by Region (USD MM, %)
TABLE 4.1 List of Some Approved SCS Devices, 2012
TABLE 4.2 List of SCS Devices Under Development, 2012
TABLE 5.1 List of Approved DBS Devices, 2012
TABLE 5.2 List of DBS Devices Under Development, 2012
TABLE 5.3 Global Population, 65 and Above - 2010, 2015 and 2020
TABLE 6.1 List of Approved VNS Devices, 2012
TABLE 6.2 List of VNS Devices Under Development, 2012
TABLE 7.1 List of Some Other Approved Neurostimulation Devices in the Market, 2012
TABLE 7.2 List of Some Neurostimulation Devices in Pipeline, 2012
TABLE 8.1 Classification of Medical Devices in the US
TABLE 8.2 Population Over 65 in the US and Selected Countries in Europe, 2010, 2015 and 2020 (%)
TABLE 11.1 Neurostimulation Devices Market, 2011 - By Leading Segments (USD MM, %)
TABLE 11.2 Neurostimulation Devices Market, 2011 - By Leading Companies (USD MM, %)
TABLE 11.3 Sales of Some Neurostimulation Devices, 2011 (USD MM)
TABLE 11.4 Neurostimulation Devices Market Forecast - By Leading Segments, 2012-2017 (USD MM)
TABLE 11.5 Market Shares of Leading Segments in the Neurostimulation Devices Market, 2011-2017 (%)
TABLE 11.6 SCS Devices Market, 2011 - By Leading Regions (USD MM, %)
TABLE 11.7 SCS Devices Market, 2011 - By Leading Companies (USD MM, %)
TABLE 11.8 SCS Devices Market Forecast - By Leading Regions, 2012-2017 (USD MM)
TABLE 11.9 Market Shares of Leading Segments in the SCS Devices Market, 2011-2017 (%)
TABLE 11.10 DBS Devices Market, 2011 - By Leading Regions (USD MM, %)
TABLE 11.11 DBS Devices Market, 2011 - By Leading Companies (USD MM, %)
TABLE 11.12 DBS Devices Market Forecast - By Leading Regions, 2012-2017 (USD MM)
TABLE 11.13 Market Shares of Leading Segments in the DBS Devices Market, 2011-2017 (%)
TABLE 11.14 VNS Devices Market, 2011 - By Leading Regions (USD MM, %)
TABLE 11.15 VNS Devices Market, 2011 - By Indications (USD MM, %)
TABLE 11.16 VNS Devices Market Forecast - By Leading Regions, 2012-2017 (USD MM)
TABLE 11.17 Market Shares of Leading Segments in the VNS Devices Market, 2011-2017 (%)
TABLE 11.18 Neurostimulation Devices Market, 2011 - By Leading Regions (USD MM, %)
TABLE 11.19 The US Neurostimulation Devices Market, 2011 - By Leading Segments (USD MM, %)
TABLE 11.20 The US Neurostimulation Devices Market, 2011 - By Leading Companies (USD MM, %)
TABLE 11.21 The US Neurostimulation Devices Market Forecast - By Leading Segments, 2012-2017 (USD MM)
TABLE 11.22 European Neurostimulation Devices Market, 2011 - By Leading Segments (USD MM, %)
TABLE 11.23 European Neurostimulation Devices Market, 2011 - By Leading Countries (USD MM, %)
TABLE 11.24 European Neurostimulation Devices Market Forecast - By Leading Segments, 2012-2017 (USD MM)
TABLE 11.25 Rest of the World Neurostimulation Devices Market Forecast - By Leading Segments, 2012-2017 (USD MM)
TABLE 11.26 Market Shares of Leading Regions in the Neurostimulation Devices Market, 2011-2017 (%)
TABLE 11.27 Medtronic - Sales by Business Segments (USD MM, %)
TABLE 11.28 Medtronic Neuromodulation Segment - Sales by Region (USD MM, %)
TABLE 11.29 St. Jude Medical - Sales by Business Segments (USD MM, %)
TABLE 11.30 St. Jude Medical Neuromodulation Segment - Sales by Region (USD MM, %)
TABLE 11.31 Boston Scientific - Sales by Business Segments (USD MM, %)
TABLE 11.32 Boston Scientific Neuromodulation Segment - Sales by Region (USD MM, %)
TABLE 11.33 Cyberonics - Sales by Region (USD MM, %)
LIST OF FIGURES
FIGURE 3.1 Neurostimulation Devices Market, 2011 – By Leading Segments (USD MM, %)
FIGURE 3.2 Neurostimulation Devices Market, 2011 - By Leading Companies (USD MM, %)
FIGURE 3.3 Sales of Some Neurostimulation Devices, 2011 (USD MM, %)
FIGURE 3.4 Neurostimulation Devices Market, 2011-2017 - By Leading Segments (USD MM)
FIGURE 3.5 Neurostimulation Devices Market, 2011-2017 - By Leading Segments (%)
FIGURE 4.1 SCS Devices Market, 2011 - By Leading Regions (USD MM, %)
FIGURE 4.2 SCS Devices Market, 2011 - By Leading Companies (USD MM, %)
FIGURE 4.3 SCS Devices Market, 2011-2017 - By Leading Regions (USD MM)
FIGURE 4.4 SCS Devices Market, 2011-2017 - Shares by Leading Regions (%)
FIGURE 5.1 Timeline for Development of DBS Therapy, 1993 - Current
FIGURE 5.2 DBS Devices Market, 2011 - By Leading Regions (USD MM, %)
FIGURE 5.3 DBS Devices Market, 2011 - By Leading Companies (USD MM, %)
FIGURE 5.4 DBS Devices Market, 2011-2017 - By Leading Regions (USD MM)
FIGURE 5.5 DBS Devices Market, 2011 - 2017 - Shares by Leading Regions (%)
FIGURE 6.1 VNS Devices Market, 2011 - By Leading Regions (USD MM, %)
FIGURE 6.2 VNS Devices Market, 2011 - By Leading Indications (USD MM, %)
FIGURE 6.3 VNS Devices Market, 2011-2017 - By Leading Regions (USD MM)
FIGURE 6.4 VNS Devices Market, 2011-2017 - Shares by Leading Regions (%)
FIGURE 8.1 Neurostimulation Devices Market, 2011 - By Regions (USD MM, %)
FIGURE 8.2 The US Neurostimulation Devices Market, 2011 - By Leading Segments (USD MM, %)
FIGURE 8.3 The US Neurostimulation Devices Market, 2011 - By Leading Companies (USD MM, %)
FIGURE 8.4 The US Neurostimulation Devices Market Forecast - By Leading Segments, 2012 - 2017 (USD MM)
FIGURE 8.5 European Neurostimulation Devices Market, 2011 - By Leading Segments (USD MM, %)
FIGURE 8.6 European Neurostimulation Devices Market, 2011 - By Leading Countries (USD MM, %)
FIGURE 8.7 European Neurostimulation Devices Market Forecast - By Leading Segments, 2012 - 2017 (USD MM)
FIGURE 8.8 Rest of the World Neurostimulation Devices Market Forecast - By Leading Segments, 2012 - 2017 (USD MM)
FIGURE 8.9 Neurostimulation Devices Market, 2011-2017 - Shares by Leading Regions (%)
FIGURE 9.1 Medtronic - Sales by Business Segments (USD MM, %)
FIGURE 9.2 Medtronic Neuromodulation Segment- Sales by Regions (USD MM, %)
FIGURE 9.3 St. Jude Medical - Sales by Business Segments (USD MM, %)
FIGURE 9.4 St. Jude Medical Neuromodulation Segment - Sales by Regions (USD MM, %)
FIGURE 9.5 Boston Scientific - Sales by Business Segments (USD MM, %)
FIGURE 9.6 Boston Scientific Neuromodulation Segment - Sales by Regions (USD MM, %)
FIGURE 9.7 Cyberonics - Sales by Regions (USD MM, %)
LIST OF COMPANIES AND ORGANISATIONS
The following companies have been mentioned in this report:
1. Advanced Neuromodulation Systems (ANS)
2. Aetna
3. Aleva Neurotherapeutics
4. Apnex Medical
5. Atrotech
6. Autonomic Technologies
7. Avery Biomedical
8. BioControl Medical
9. Bio-Medical Research (BMR)
10. Boston Scientific
11. Cerbomed
12. CerebralRx
13. CVRx
14. Cyberonics
15. Device Technologies Australia Pty Limited
16. ElectroCore
17. Empire Blue
18. EnteroMedics
19. General Electronic (GE)
20. Greatbach
21. ImThera Medical
22. Inspire Medical Systems
23. Intelect Medical
24. IntraPace
25. Johnson & Johnson
26. Mayo Clinic
27. Medtronic
28. MetaCure
29. MicroTransponder
30. Neurologix
31. Neuronetics
32. NeuroPace
33. Neuros Medical
34. NeuroSigma
35. Neurotech
36. Neurowave Medical Technologies
37. Nevro Corporation
38. Nihon Kohden Corporation
39. Respicardia
40. Royal Philips Electronics
41. Sapiens Steering Brain Stimulation
42. SetPoint Medical
43. Spinal Modulation
44. SPR Therapeutics
45. St. Jude Medical
46. Synapse Biomedical
47. Uroplasty
The following organisations have been mentioned in this report:
1. American Urological Association
2. Australian Therapeutic Goods Administration (ATGA)
3. Centers for Medicare and Medicaid Services (CMS)
4. Chiba University
5. Chinese SFDA
6. Epilepsy Foundation
7. European Commission (EC)
8. Food and Drug Administration (FDA)
9. Großhadern Hospital
10. Health Canada
11. Johns Hopkins University School of Medicine
12. Medical Devices Advisory Committee (MDAC)
13. Medicines and Healthcare Products Regulatory Agency (MHRA)
14. Ministry of Health, Labour and Welfare (MHLW)
15. Motor Neurone Disease Association
16. National Center Hospital, Tokyo
17. National Institute for Health and Clinical Excellence (NICE)
18. Northwestern University
19. Pharmaceuticals and Medical Devices Agency (PMDA)
20. United Nations Population Division (UNPD)
21. University of Toronto
22. World Health Organization (WHO)
FIGURE 3.1 Neurostimulation Devices Market, 2011 – By Leading Segments (USD MM, %)
FIGURE 3.2 Neurostimulation Devices Market, 2011 - By Leading Companies (USD MM, %)
FIGURE 3.3 Sales of Some Neurostimulation Devices, 2011 (USD MM, %)
FIGURE 3.4 Neurostimulation Devices Market, 2011-2017 - By Leading Segments (USD MM)
FIGURE 3.5 Neurostimulation Devices Market, 2011-2017 - By Leading Segments (%)
FIGURE 4.1 SCS Devices Market, 2011 - By Leading Regions (USD MM, %)
FIGURE 4.2 SCS Devices Market, 2011 - By Leading Companies (USD MM, %)
FIGURE 4.3 SCS Devices Market, 2011-2017 - By Leading Regions (USD MM)
FIGURE 4.4 SCS Devices Market, 2011-2017 - Shares by Leading Regions (%)
FIGURE 5.1 Timeline for Development of DBS Therapy, 1993 - Current
FIGURE 5.2 DBS Devices Market, 2011 - By Leading Regions (USD MM, %)
FIGURE 5.3 DBS Devices Market, 2011 - By Leading Companies (USD MM, %)
FIGURE 5.4 DBS Devices Market, 2011-2017 - By Leading Regions (USD MM)
FIGURE 5.5 DBS Devices Market, 2011 - 2017 - Shares by Leading Regions (%)
FIGURE 6.1 VNS Devices Market, 2011 - By Leading Regions (USD MM, %)
FIGURE 6.2 VNS Devices Market, 2011 - By Leading Indications (USD MM, %)
FIGURE 6.3 VNS Devices Market, 2011-2017 - By Leading Regions (USD MM)
FIGURE 6.4 VNS Devices Market, 2011-2017 - Shares by Leading Regions (%)
FIGURE 8.1 Neurostimulation Devices Market, 2011 - By Regions (USD MM, %)
FIGURE 8.2 The US Neurostimulation Devices Market, 2011 - By Leading Segments (USD MM, %)
FIGURE 8.3 The US Neurostimulation Devices Market, 2011 - By Leading Companies (USD MM, %)
FIGURE 8.4 The US Neurostimulation Devices Market Forecast - By Leading Segments, 2012 - 2017 (USD MM)
FIGURE 8.5 European Neurostimulation Devices Market, 2011 - By Leading Segments (USD MM, %)
FIGURE 8.6 European Neurostimulation Devices Market, 2011 - By Leading Countries (USD MM, %)
FIGURE 8.7 European Neurostimulation Devices Market Forecast - By Leading Segments, 2012 - 2017 (USD MM)
FIGURE 8.8 Rest of the World Neurostimulation Devices Market Forecast - By Leading Segments, 2012 - 2017 (USD MM)
FIGURE 8.9 Neurostimulation Devices Market, 2011-2017 - Shares by Leading Regions (%)
FIGURE 9.1 Medtronic - Sales by Business Segments (USD MM, %)
FIGURE 9.2 Medtronic Neuromodulation Segment- Sales by Regions (USD MM, %)
FIGURE 9.3 St. Jude Medical - Sales by Business Segments (USD MM, %)
FIGURE 9.4 St. Jude Medical Neuromodulation Segment - Sales by Regions (USD MM, %)
FIGURE 9.5 Boston Scientific - Sales by Business Segments (USD MM, %)
FIGURE 9.6 Boston Scientific Neuromodulation Segment - Sales by Regions (USD MM, %)
FIGURE 9.7 Cyberonics - Sales by Regions (USD MM, %)
LIST OF COMPANIES AND ORGANISATIONS
The following companies have been mentioned in this report:
1. Advanced Neuromodulation Systems (ANS)
2. Aetna
3. Aleva Neurotherapeutics
4. Apnex Medical
5. Atrotech
6. Autonomic Technologies
7. Avery Biomedical
8. BioControl Medical
9. Bio-Medical Research (BMR)
10. Boston Scientific
11. Cerbomed
12. CerebralRx
13. CVRx
14. Cyberonics
15. Device Technologies Australia Pty Limited
16. ElectroCore
17. Empire Blue
18. EnteroMedics
19. General Electronic (GE)
20. Greatbach
21. ImThera Medical
22. Inspire Medical Systems
23. Intelect Medical
24. IntraPace
25. Johnson & Johnson
26. Mayo Clinic
27. Medtronic
28. MetaCure
29. MicroTransponder
30. Neurologix
31. Neuronetics
32. NeuroPace
33. Neuros Medical
34. NeuroSigma
35. Neurotech
36. Neurowave Medical Technologies
37. Nevro Corporation
38. Nihon Kohden Corporation
39. Respicardia
40. Royal Philips Electronics
41. Sapiens Steering Brain Stimulation
42. SetPoint Medical
43. Spinal Modulation
44. SPR Therapeutics
45. St. Jude Medical
46. Synapse Biomedical
47. Uroplasty
The following organisations have been mentioned in this report:
1. American Urological Association
2. Australian Therapeutic Goods Administration (ATGA)
3. Centers for Medicare and Medicaid Services (CMS)
4. Chiba University
5. Chinese SFDA
6. Epilepsy Foundation
7. European Commission (EC)
8. Food and Drug Administration (FDA)
9. Großhadern Hospital
10. Health Canada
11. Johns Hopkins University School of Medicine
12. Medical Devices Advisory Committee (MDAC)
13. Medicines and Healthcare Products Regulatory Agency (MHRA)
14. Ministry of Health, Labour and Welfare (MHLW)
15. Motor Neurone Disease Association
16. National Center Hospital, Tokyo
17. National Institute for Health and Clinical Excellence (NICE)
18. Northwestern University
19. Pharmaceuticals and Medical Devices Agency (PMDA)
20. United Nations Population Division (UNPD)
21. University of Toronto
22. World Health Organization (WHO)
